Context Therapeutics Inc.: insider trades · United States · SEC (Form 4)

About Context Therapeutics Inc.

Context Therapeutics Inc. (ticker: CNTX) is a U.S.-listed biopharmaceutical company trading on Nasdaq in the United States. For European investors, it fits the profile of an early-stage oncology biotech: highly research-intensive, capital-hungry, and driven by clinical milestones rather than near-term commercial revenue. The company is headquartered in Philadelphia, Pennsylvania, which remains its operational base and the center of its public communications and development work. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001842952/000184295225000044/cntx10-kdec312024.pdf?utm_source=openai)) Context was founded in April 2015 as Context Therapeutics LLC and later evolved into a public company. Its earlier strategy focused on hormone-driven female cancers, but over time the company shifted toward next-generation T cell engaging bispecific antibodies for solid tumors. That strategic repositioning is important: it moved Context from a narrower women’s oncology story into a broader immuno-oncology platform, while still retaining a highly specialized development model. Its IPO on Nasdaq in 2021 was a key financing and visibility event that helped support the transition into a clinical-stage company. ([ir.contexttherapeutics.com](https://ir.contexttherapeutics.com/static-files/2183d3ae-2f63-4ab2-ad2e-90d438b33aa4?utm_source=openai)) Today, the pipeline is anchored by three lead programs. CTIM-76 is a CLDN6 x CD3 bispecific antibody; CT-95 is a mesothelin-directed, avidity-enhanced MSLN x CD3 bispecific; and CT-202 is a dual pH-dependent Nectin-4 x CD3 bispecific. These programs are designed to harness T-cell activity against solid tumors while aiming for better tumor selectivity and a more manageable safety profile than earlier generations of T-cell engagers. In competitive terms, Context is a focused specialist rather than a diversified pharma player, competing in a crowded field that includes large pharmaceutical companies and numerous biotech peers pursuing similar mechanisms. ([contexttherapeutics.com](https://www.contexttherapeutics.com/?utm_source=openai)) The company’s recent news flow has been driven by clinical progress. In 2025, Context reported ongoing Phase 1 dose-escalation studies for CTIM-76 and CT-95, presented preclinical and translational data at major scientific meetings, and reiterated that CT-202 was expected to advance toward an IND filing in mid-2026. These are the kinds of updates investors monitor closely because they define the company’s next value inflection points, regulatory trajectory, and funding needs. ([ir.contexttherapeutics.com](https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-reports-second-quarter-2025-operating-and?utm_source=openai)) From an investor perspective, Context Therapeutics is a classic Nasdaq-listed clinical oncology story: potentially high upside if early data continue to support the platform, but with substantial execution, safety, and financing risk. The company’s current positioning is most relevant to investors seeking exposure to immuno-oncology innovation in the United States, with a pipeline concentrated on difficult-to-treat solid tumors and a management narrative centered on disciplined clinical advancement. ([ir.contexttherapeutics.com](https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-reports-third-quarter-2025-operating-and?utm_source=openai))